Treatment (IU/ml)a | Mean no. of plaquesb ± SEM | Fold reductionc | |
---|---|---|---|
HSV-2 MS | Vehicle | 137 ± 8.3 | - |
IFN-α (100) | 82.5 ± 6.4 | 1.7 | |
IFN-γ (100) | 86 ± 6.6 | 1.6 | |
IFN-α (100)+IFN-γ (100) | 36.5 ± 4.3 | 3.8 | |
IFN-α (200) | 68 ± 5.8 | 2 | |
IFN-γ (200) | 72 ± 6 | 1.9 | |
HSV-2 G | Vehicle | 98.5 ± 7 | - |
IFN-α (100) | 81 ± 6.4 | 1.2 | |
IFN-γ (100) | 98 ± 7 | 1 | |
IFN-α (100) + IFN-γ (100) | 11.5 ± 2.4 | 8.6 | |
IFN-α (200) | 52 ± 5.1 | 1.9 | |
IFN-γ (200) | 35 ± 4.2 | 2.8 | |
HSV-1 KOS | Vehicle | 133 ± 8.2 | - |
IFN-α (100) | 68.5 ± 5.9 | 1.9 | |
IFN-γ (100) | 74.5 ± 6.1 | 1.8 | |
IFN-α (100) + IFN-γ (100) | 4 ± 1.4 | 33 | |
IFN-α (200) | 54.5 ± 5.2 | 2.4 | |
IFN-γ (200) | 84.5 ± 6.5 | 1.6 | |
HSV-1 F | Vehicle | 100 ± 7.1 | - |
IFN-α (100) | 82.5 ± 6.4 | 1.2 | |
IFN-γ (100) | 84.5 ± 6.5 | 1.2 | |
IFN-α (100) + IFN-γ (100) | 19 ± 3.1 | 5.3 | |
IFN-α (200) | 51.5 ± 5.1 | 1.9 | |
IFN-γ (200) | 53 ± 5.1 | 1.9 |